Security key
252828108
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH)
CUSIP: 252828108
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 54,411,104
- Total 13F shares
- 61,188,245
- Share change
- +12,743,952
- Total reported value
- $5,142,942,810
- Put/Call ratio
- 110%
- Price per share
- $83.92
- Number of holders
- 238
- Value change
- +$1,101,399,524
- Number of buys
- 170
- Number of sells
- 72
Report period
Q1 2026
Institutions
238
Top holders
10
DNTH full security history
Previous quarter: Q4 2025
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Broader feeds
Reporting periods
Holder history for CUSIP 252828108
Recent filing periods:
Top shareholders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
15%
from 13D/G
|
6,431,329
|
$265,035,068 | — | 31 Dec 2025 | |
| Sirenia Capital Management LP |
13D/G
|
— |
5.3%
|
2,798,122
|
$256,475,863 | $0 | 31 Mar 2026 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.1%
|
2,634,004
|
$221,045,616 | +$86,760,776 | 31 Mar 2026 | |
| Fairmount Funds Management LLC |
13F
13D/G
3/4/5
|
Company · Director |
4.9%
from 13D/G
|
2,137,191
|
$88,073,641 | — | 31 Dec 2025 | |
| Avidity Partners Management LP |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
2,104,184
|
$86,713,423 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
4.8%
|
2,611,733
|
$239,391,447 | $0 | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
4.8%
|
2,595,783
|
$237,929,470 | +$1,660,971 | 31 Mar 2026 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
4.7%
|
1,501,624
|
$32,660,322 | $0 | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13D/G
13F
|
Company |
3.6%
|
1,946,667
|
$178,431,497 | -$43,080,200 | 31 Mar 2026 | |
| BCLS Fund III Investments, LP |
13D/G
|
— |
3.1%
|
1,315,892
|
$51,780,350 | -$45,896,187 | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
3.1%
|
1,000,000
|
$20,060,000 | $0 | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13D/G
|
— |
3%
|
1,180,000
|
$46,433,000 | -$79,487,000 | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
1.2%
|
643,599
|
$58,992,284 | -$214,307,954 | 31 Mar 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
2,048,452
|
$84,416,707 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
3.1%
|
1,676,624
|
$69,093,675 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.8%
|
1,507,619
|
$62,128,979 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
2.3%
|
1,273,935
|
$52,498,861 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2%
|
1,068,934
|
$44,050,770 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.9%
|
1,008,533
|
$41,561,643 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.8%
|
1,004,728
|
$41,404,841 | — | 31 Dec 2025 | |
| Venrock Adviser, LLC |
13F
|
Company |
1.8%
|
1,000,000
|
$41,210,000 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.5%
|
834,383
|
$34,384,923 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.5%
|
789,759
|
$32,545,968 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
750,136
|
$30,913,105 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
1.4%
|
743,592
|
$30,643,426 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
676,658
|
$27,890,189 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.2%
|
667,216
|
$27,495,971 | — | 31 Dec 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
1.2%
|
653,572
|
$26,933,702 | — | 31 Dec 2025 | |
| Tri Locum Partners LP |
13F
|
Company |
1.1%
|
622,403
|
$25,649,228 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.1%
|
616,033
|
$25,388,000 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
606,620
|
$24,998,811 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
577,019
|
$23,778,953 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.87%
|
475,749
|
$19,605,616 | — | 31 Dec 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.87%
|
474,503
|
$19,554,269 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.86%
|
465,538
|
$19,184,821 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.85%
|
462,826
|
$19,073,059 | — | 31 Dec 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.69%
|
375,000
|
$15,453,750 | — | 31 Dec 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.65%
|
353,998
|
$14,588,258 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.64%
|
350,000
|
$14,423,500 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.58%
|
315,000
|
$12,981,150 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.57%
|
311,150
|
$12,823,037 | — | 31 Dec 2025 | |
| Spruce Street Capital LP |
13F
|
Company |
0.55%
|
297,437
|
$12,257,379 | — | 31 Dec 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.51%
|
275,000
|
$11,332,750 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.49%
|
264,692
|
$10,907,958 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.46%
|
250,812
|
$10,335,963 | — | 31 Dec 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.45%
|
246,788
|
$10,170,133 | — | 31 Dec 2025 | |
| Iron Triangle Partners LP |
13F
|
Company |
0.42%
|
230,730
|
$9,508,383 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.42%
|
228,016
|
$9,396,579 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.39%
|
213,087
|
$8,781,315 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.39%
|
210,673
|
$8,681,773 | — | 31 Dec 2025 |
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) as of Q1 2026
As of 31 Mar 2026,
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) was held by
238 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,188,245 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., WELLINGTON MANAGEMENT GROUP LLP, Fairmount Funds Management LLC, Avidity Partners Management LP, VANGUARD CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, TCG Crossover Management, LLC, and CITADEL ADVISORS LLC.
This page lists
238
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
167
Q1 2026 holders
238
Holder diff
71
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.